AVE plans to increase its investment in Luying Technology by 10 million yuan, with its core products being SPECT and SPECT/CT and their core components
AVE announced plans to increase its investment in Luying Technology by 10 million yuan using its own funds. After the investment, it will hold a 9.0744% stake in Luying Technology. Luying Technology focuses on the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components, providing precise, safe, economical, and convenient molecular imaging diagnostic technology solutions
According to the announcement from Zhitong Finance APP, AVE (688067.SH) announced that the company has invested 10 million yuan in Luying Technology using its own funds for capital increase. After the capital increase is completed, the company will hold 9.0744% of the equity in Luying Technology. According to the announcement information, Luying Technology's main business is the development of domestically produced high-resolution single-photon emission computed tomography (SPECT) and its core components, providing hospitals with precise, safe, economical, and convenient molecular imaging diagnostic technology solutions. The core products are domestically produced SPECT and SPECT/CT and their core components, which belong to high-end nuclear medicine imaging and diagnostic equipment
